141 related articles for article (PubMed ID: 25955428)
1. A mathematical model to elucidate brain tumor abrogation by immunotherapy with T11 target structure.
Banerjee S; Khajanchi S; Chaudhuri S
PLoS One; 2015; 10(5):e0123611. PubMed ID: 25955428
[TBL] [Abstract][Full Text] [Related]
2. Quantifying the role of immunotherapeutic drug T11 target structure in progression of malignant gliomas: Mathematical modeling and dynamical perspective.
Khajanchi S; Banerjee S
Math Biosci; 2017 Jul; 289():69-77. PubMed ID: 28461156
[TBL] [Abstract][Full Text] [Related]
3. Influence of multiple delays in brain tumor and immune system interaction with T11 target structure as a potent stimulator.
Khajanchi S; Banerjee S
Math Biosci; 2018 Aug; 302():116-130. PubMed ID: 29908145
[TBL] [Abstract][Full Text] [Related]
4. Disease relevance of T11TS-induced T-cell signal transduction through the CD2-mediated calcineurin-NFAT pathway: Perspectives in glioma immunotherapy.
Chaudhuri S; Bhattacharya D; Singh MK; Moitra S; Ronsard L; Ghosh TK; Chaudhuri S
Mol Immunol; 2015 Oct; 67(2 Pt B):256-64. PubMed ID: 26105805
[TBL] [Abstract][Full Text] [Related]
5. T11 target structure exerts effector function by activating immune cells in CNS against glioma where cytokine modulation provide favorable microenvironment.
Ghosh A; Bhattacharya M; Sarkar P; Acharya S; Chaudhuri S
Indian J Exp Biol; 2010 Sep; 48(9):879-88. PubMed ID: 21506495
[TBL] [Abstract][Full Text] [Related]
6. [Cellular immunotherapy for malignant glioma].
Okamoto Y; Yamashita J
Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
[No Abstract] [Full Text] [Related]
7. The mixed human umbilical cord blood-derived mesenchymal stem cells show higher antitumor effect against C6 cells than the single in vitro.
Jiao H; Yang B; Guan F; Li J; Shan H; Song L; Hu X; Liang S; Du Y; Jiang C
Neurol Res; 2011 May; 33(4):405-14. PubMed ID: 21535940
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory role of TIITS in respect to cytotoxic lymphocytes in four grades of human glioma.
Kumar P; Acharya S; Chatterjee S; Kumari A; Chaudhuri S; Singh MK; Ghosh SN; Chaudhuri S
Cell Immunol; 2012; 276(1-2):176-86. PubMed ID: 22704241
[TBL] [Abstract][Full Text] [Related]
9. Significant modulation of macrophages associated cytokines TNF-α, VEGF and apoptotoic protein Bax, Bcl2 abrogates tumor cells.
Kumar P; Chatterjee S; Acharya S; Kumari A; Chaudhuri S; Singh MK; Ghosh SN; Chaudhuri S
Cell Immunol; 2013; 284(1-2):172-81. PubMed ID: 23994239
[TBL] [Abstract][Full Text] [Related]
10. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
Yamanaka R; Xanthopoulos KG
DNA Cell Biol; 2005 May; 24(5):317-24. PubMed ID: 15869409
[TBL] [Abstract][Full Text] [Related]
11. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics.
Kronik N; Kogan Y; Vainstein V; Agur Z
Cancer Immunol Immunother; 2008 Mar; 57(3):425-39. PubMed ID: 17823798
[TBL] [Abstract][Full Text] [Related]
12. CD2-SLFA3/T11TS interaction facilitates immune activation and glioma regression by apoptosis.
Sarkar S; Ghosh A; Mukherjee J; Chaudhuri S; Chaudhuri S
Cancer Biol Ther; 2004 Nov; 3(11):1121-8. PubMed ID: 15467439
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with T11TS / S-LFA-3 specifically induces apoptosis of brain tumor cells by augmenting intracranial immune status.
Mukherjee J; Ghosh A; Sarkar P; Mazumdar M; Banerjee C; Chaudhuri S
Anticancer Res; 2005; 25(4):2905-19. PubMed ID: 16080544
[TBL] [Abstract][Full Text] [Related]
14. Focused ultrasound-induced blood-brain barrier opening to enhance interleukin-12 delivery for brain tumor immunotherapy: a preclinical feasibility study.
Chen PY; Hsieh HY; Huang CY; Lin CY; Wei KC; Liu HL
J Transl Med; 2015; 13():93. PubMed ID: 25784614
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors.
Eberstål S; Sandén E; Fritzell S; Darabi A; Visse E; Siesjö P
Int J Cancer; 2014 Jun; 134(11):2748-53. PubMed ID: 24243648
[TBL] [Abstract][Full Text] [Related]
16. Impaired capacity for upregulation of MHC class II in tumor-associated microglia.
Schartner JM; Hagar AR; Van Handel M; Zhang L; Nadkarni N; Badie B
Glia; 2005 Sep; 51(4):279-85. PubMed ID: 15818597
[TBL] [Abstract][Full Text] [Related]
17. T11TS inhibits Angiopoietin-1/Tie-2 signaling, EGFR activation and Raf/MEK/ERK pathway in brain endothelial cells restraining angiogenesis in glioma model.
Bhattacharya D; Chaudhuri S; Singh MK; Chaudhuri S
Exp Mol Pathol; 2015 Jun; 98(3):455-66. PubMed ID: 25797371
[TBL] [Abstract][Full Text] [Related]
18. Immunologic approaches to therapy for brain tumors.
Paul DB; Kruse CA
Curr Neurol Neurosci Rep; 2001 May; 1(3):238-44. PubMed ID: 11898524
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells.
Badn W; Hegardt P; Fellert MA; Darabi A; Esbjörnsson M; Smith KE; Janelidze S; Salford LG; Visse E; Siesjö P
Scand J Immunol; 2007 Mar; 65(3):289-97. PubMed ID: 17309784
[TBL] [Abstract][Full Text] [Related]
20. Intracerebral interleukin 12 induces glioma rejection in the brain predominantly by CD8+ T cells and independently of interferon-gamma.
Vetter M; Hofer MJ; Roth E; Pircher HP; Pagenstecher A
J Neuropathol Exp Neurol; 2009 May; 68(5):525-34. PubMed ID: 19525900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
